Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New app aims to keep pregnancy weight gain in check

NCT ID NCT05807594

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a digital platform called HMZ 2.0 that helps pregnant women with overweight or obesity manage their weight gain. 144 women will be randomly assigned to use the platform or receive standard pregnancy advice. The platform tracks weight, activity, and eating, and offers personalized coaching from a dietitian. The goal is to see if this approach can help women stay within healthy weight gain guidelines and improve outcomes for both mother and baby.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital platform with personalized coaching and monitoring
What this could lead to
If successful, this could provide an effective, scalable tool to help pregnant women manage weight gain, potentially improving health outcomes for mothers and babies.
What could go wrong
This is a relatively small early-stage trial (144 participants), so results may not apply to all pregnant women. The intervention requires daily self-monitoring and weekly sessions, which may be burdensome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women * ≥ 8 and \< 18 weeks gestation at time of screening. This range of gestational age is chosen to: a) reduce chances of false pregnancy or miscarriage under 8 weeks gestation and b) recruit women in the 1st trimester for greatest impact of the intervention on gestational weight gain. In the feasibility and initial impact study, the investigators had less than 10% (n=3) miscarriages prior to randomization using these criteria * Singleton gestation * Not currently heavily smoking (\>20 cigarettes/day) * Any parity (i.e., first-time pregnancy, second pregnancy, etc.) * Any race/ethnicity * Ages 18-45 years * Body mass index (BMI) range 20.0 to 45.0. If BMI is over 40, consultation with woman's health care provider will be made to determine eligibility and ensure she does not have any contraindications to physical activity or other concerns with intervention participation. * Haven't exceeded 25% or more of their total GWG (based on BMI and IOM guidelines) from pre-pregnancy to date of enrollment. * Participant has physician consent to confirm subject participation * Able to read, understand, and speak English * Access to a computer/phone * Willingness and ability to complete study materials and intervention sessions electronically (e.g., email, Facetime, Zoom), at home (e.g., Zoom sessions delivered synchronous and asynchronous) or if requested by the participant, on-site at Penn State University Park or Hershey campuses. * No current use of weight loss medications * No current participation in another interventional study or program that influences weight control * No planned bariatric surgery during this current pregnancy * No absolute contraindications to exercise in pregnancy and relative contraindications with provider consent (see below) Exclusion Criteria: * Not pregnant women * Men (unable to become pregnant) * Multiple gestation * \< 8 weeks gestation or \> 18 weeks gestation at time of pre-intervention assessment * Currently smoking \> 20 cigarettes/day * Outside of the age range of 18-45 years * Outside of the BMI range of 20.0-45.0 * Exceeded 25% of their total GWG (based on BMI and IOM guidelines) from pre-pregnancy to date of enrollment * Not able to read and/or understand English * Unable to access materials by computer or phone (even with data plan assistance if necessary) * Current use of weight loss medications * Current participation in another interventional study or program that influences weight control * Planned bariatric surgery during this current pregnancy * Contraindications to aerobic exercise in pregnancy: Absolute contraindications to exercise: * Hemodynamically significant heart disease * Restrictive lung disease (pulmonary fibrosis, sarcoidosis, pleural effusion, neuromuscular disease). This DOES NOT include ASTHMA * Incompetent cervix/cerclage * Severe anemia * Multiple gestation at risk for premature labor * Persistent 2nd or 3rd trimester bleeding * Placenta previa after 26 weeks gestation * Premature labor during the current pregnancy * Ruptured membranes * Poorly controlled chronic hypertension * Preeclampsia diagnosis during current pregnancy * Poorly controlled Type 1 diabetes Relative contraindications to exercise (if permission is not given by provider): * Unevaluated maternal cardiac arrhythmia * Chronic bronchitis * Extreme morbid obesity (BMI \> 40.0; needs provider consent to participate) * Extreme underweight (BMI \< 12.0) * History of extremely sedentary lifestyle * Current eating disorder(s) diagnosis * Severe food allergies and/or dietary restrictions that may preclude study participation. * Intrauterine growth restriction in current pregnancy * Poorly controlled respiratory disorder (severe asthma) that precludes study participation * Orthopedic limitations * Poorly controlled seizure disorder * Poorly controlled thyroid disease * Uncontrolled sleep disorder (insomnia, sleep-disordered breathing)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Energy balance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gestational Weight Gain Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pennsylvania State University

    RECRUITING

    University Park, Pennsylvania, 16802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.